February 14th 2025
Your daily dose of the clinical news you may have missed.
February 3rd 2025
Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.
January 30th 2025
The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.
October 29th 2024
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
October 23rd 2024
Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.
Respiratory Syncytial Virus: A Year of Infant Protection Breakthroughs
The world's first maternal vaccine against RSV in neonates and infants was approved in August. This brief slide show highlights the clinical trials that made history.
Pfizer Wins FDA Approval for Vaccine against RSV in Older Adults
The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.
Adult RSV Vaccine: How Will Older Adults React to New Kid on the Block?
Delivering 3 vaccines to older adults is going to be a challenge this fall, says Dr William Schaffner.
Robust RSV Surveillance Data Will be Key to Getting US Clinicians Comfortable with New Adult Vaccine
Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.
Are US Seniors Ready for an RSV Vaccine? Consider the Lessons of COVID-19, says Dr Kelly Moore
Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.
GSK Adult RSV Vaccine: Expert Highlights Path to FDA Approval
Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.
GSK Adult RSV Vaxx: Public Health Expert Reviews Topics for ACIP Meeting in June
Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.
First RSV Vaccine Brings "Sense of Relief" to Public Health Experts, Says Immunize.org President
Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."
FDA Approves World's First Vaccine Against Respiratory Syncytial Virus
The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.
RSV Circulation Approximating Prepandemic Seasonality, Suggest New CDC Data
Onset of the 2022-2023 RSV season and its end were closer to historical patterns but atypical circulation may continue, say researchers writing in MMWR.
